Quarter
Charts

NEUROCRINE BIOSCIENCES INC

NBIX

CIK 0000914475 · Quarterly mode · latest period FY2025 (Q4) (ending 2025-12-31) · sourced from SEC EDGAR

At a glance · FY2025 (Q4)

Revenue
$806M
↑+28.3% +$178Mvs FY2024 (Q4)
Operating Income
$211M
↑+48.5% +$69Mvs FY2024 (Q4)
Net Income
$154M
↑+49.1% +$51Mvs FY2024 (Q4)
Gross Profit
$788M
↑+27.4% +$170Mvs FY2024 (Q4)

Quality Score

Quality score

6-dimension fundamental snapshot · latest annual filed values · S&P 500 calibration

Average
47/100
  • Profitability
    47ROIC 14.4% (10% = solid, 20%+ = moat)
  • Liquidity
    100Current Ratio 3.39 (above 1.5 = solid)
  • Leverage
    0Insufficient data
  • Efficiency
    37Asset Turnover 0.69x (1.0+ = capital-efficient)
  • Growth
    100Revenue YoY +28.3% (10% = solid, 25%+ = elite)
  • Margin Trend
    0Op Margin 26.2% · trend -3.6pts (4Q avg vs prior 4Q)

Calibrated to S&P 500 medians. Each sub-score is computed from a single CFA-grade ratio (Profitability = ROIC, Liquidity = Current Ratio, Leverage = D/E, Efficiency = Asset Turnover, Growth = Revenue YoY, Margin Trend = 4Q operating-margin avg vs prior 4Q). Overall = simple mean.

DCF intrinsic value

DCF intrinsic value

two-stage Gordon model

Project NBIX's free cash flow forward, discount back at your hurdle rate, divide by diluted shares. Edit the assumptions to see how sensitive the intrinsic value is.

25%

Trailing 3-yr CAGR was 32.4%

10%

10% is a common all-equity benchmark for US large-caps

2.5%

Should be ≤ long-run GDP growth (~2.5% nominal)

5

5-year explicit projection + perpetuity terminal

Intrinsic value per share
$243.63
Total enterprise IV
$24.97B
Diluted shares
0.10B
Terminal PV
$19.39B (78% of total)
Year-5 FCF
$2.28B
YearProjected FCFDiscounted PV
+1$936M$851M
+2$1.17B$967M
+3$1.46B$1.10B
+4$1.83B$1.25B
+5$2.28B$1.42B
Terminal$31.23B$19.39B

DCF outputs are HIGHLY sensitive to growth + WACC assumptions. A 1pp WACC change can shift IV by 20%+. Use this as a sanity-check vs market price, not a target — and always cross-check the underlying FCF source (EDGAR cashflow statement, latest annual). Margin of safety convention: 30-50% discount to IV before buying.

Capital allocation · trailing 4 quarters

how the company spent its cash
Capex (TTM)
$36M
investment in PP&E
Stock buybacks (TTM)
$168M
share count reduction
Stock-based comp (TTM)
$218M
non-cash dilution

Balance sheet · 2025-12-31

latest filed snapshot
Total assets
$4.63B
everything owned
Total liabilities
$1.38B
everything owed
Stockholders' equity
$3.25B
shareholder claim

Recent performance · 63 quarters

Revenue↑+28.3% +$178M
$806M
Net Income↑+49.1% +$51M
$154M
Free Cash Flow↑+65.1% +$153M
$388M
Operating Margin↑+3.6pts
26.2%

Drill down

NBIX Sankey

See NEUROCRINE BIOSCIENCES INC's revenue flow into every line item of the income statement and balance sheet — every dollar accounted for, with prior-period comparison.

Open Sankey

NBIX Charts

63 quarters of historical line items — Income, Cash Flow, Balance Sheet, plus margins. Click any chart for the trend dialog.

Open Charts

NBIX Key Metrics

EPS, BVPS, FCF/Share, ROE, ROA, ROIC, D/E, Current Ratio, Quick Ratio, Asset Turnover — 10 CFA-grade fundamentals derived from EDGAR data.

Open Key Metrics